Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

3 of 0 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04234113Phase 1Terminated

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Role: lead

NCT05120271Phase 1Active Not Recruiting

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

Role: collaborator

NCT05256381Phase 2Terminated

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Role: lead

NCT05619172Phase 2Terminated

A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

Role: lead

NCT06163391Phase 1Recruiting

A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

Role: lead

All 5 trials loaded